World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5635)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

191

WORD

HTML

1997

Figures (1-4)

500

Tables (1-4)

489

Sum=3196

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

268

Download

1153

Sum=1421

Publishing Process of This Article

Item

Count

Browse

179

Download

657

Sum=836

Jan 27, 2024 (publication date) through Jan 1, 2026

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Yang HJ, Ye B, Liao JX, Lei L, Chen K. Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Hepatol 2024; 16(1): 91-102 [PMID: 38313249 DOI: 10.4254/wjh.v16.i1.91]
URL:	https://www.wjgnet.com/1948-5182/full/v16/i1/91.htm

Number	Citing Articles
1	Mei Xu, Si-Rui Zhou, Ya-Ling Li, Chen-Hao Zhang, Da-Zhong Liao, Xiao-Li Wang. Efficacy of sorafenib combined with transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma: A meta-analysis. World Journal of Gastrointestinal Oncology 2025; 17(2): 98927 doi: 10.4251/wjgo.v17.i2.98927 Abstract(457) \| Core Tip(414) \| Full Article(HTML)(1338) \| Full Article with Cover (PDF)-11630K(119) \| Audio-2528K(4) \| Peer-Review Report-226K(75) \| Answering Reviewers-229K(71) \| Full Article (PDF)-11370K(105) \| Full Article (XML)-139K(82) \| Times Cited (0) \| Total Visits (4304) \| Open
2	Xianzhuo Yuan, Luyu Jing, Jingyuan Zhou, Chengji Dong, Ping Zhang. Combined treatments based on interventional therapy improve the prognosis of patients with HCC: an umbrella review of systematic reviews and meta-analyses. European Journal of Surgical Oncology 2026; 52(1): 111178 doi: 10.1016/j.ejso.2025.111178
3	Lixiu Yu, Yi Xiong, Jing Liao, Yahui Deng, Xuejia Zhai. Efficacy and safety of sorafenib combined with transarterial chemoembolization in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1640879
4	Licong Liang, Jingwen Zhou, Jingjun Huang, Yongjian Guo, Zhimei Zhou, Ye Chen, Liteng Lin, Xiaoyang Hong, Wenbo Shi, Zhaoyi Lin, Juan Liu, Kangshun Zhu, Wensou Huang, Mingyue Cai. Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study. ImmunoTargets and Therapy 2025; : 1187 doi: 10.2147/ITT.S543741